Nature versus nurture: the impact of nativity and site of treatment on survival for gastric cancer.
Ethnicity
Gastric cancer
Nativity
Outcomes
Survival
Treatment
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
30
05
2018
accepted:
18
08
2018
pubmed:
1
9
2018
medline:
4
9
2019
entrez:
1
9
2018
Statut:
ppublish
Résumé
The prognosis of gastric cancer patients is better in Asia than in the West. Genetic, environmental, and treatment factors have all been implicated. We sought to explore the extent to which the place of birth and the place of treatment influences survival outcomes in Korean and US patients with localized gastric cancer. Patients with localized gastric adenocarcinoma undergoing potentially curative gastrectomy from 1989 to 2010 were identified from the SEER registry and two single institution databases from the US and Korea. Patients were categorized into three groups: Koreans born/treated in Korea (KK), Koreans born in Korea/treated in the US (KUS), and White Americans born/treated in the US (W), and disease-specific survival rates compared. We identified 16,622 patients: 3,984 (24.0%) KK, 1,046 (6.3%) KUS, and 11,592 (69.7%) W patients. KK patients had longer unadjusted median (not reached) and 5-year disease-specific survival (81.6%) rates than KUS (87 months, 55.9%) and W (35 months, 39.2%; p < 0.001 for all comparisons) patients. This finding persisted on subset analyses of patients with stage IA tumors, without cardia/GEJ tumors, with > 15 examined lymph nodes, and treated at a US center of excellence. On multivariable analysis, KUS (HR 2.80, p < 0.001) and W (HR 5.79, p < 0.001) patients had an increased risk of mortality compared to KK patients. Both the place of birth and the place of treatment significantly contribute to the improved prognosis of patients with gastric cancer in Korea relative to those in the US, implicating both nature and nurture in this phenomenon.
Sections du résumé
BACKGROUND
The prognosis of gastric cancer patients is better in Asia than in the West. Genetic, environmental, and treatment factors have all been implicated. We sought to explore the extent to which the place of birth and the place of treatment influences survival outcomes in Korean and US patients with localized gastric cancer.
METHODS
Patients with localized gastric adenocarcinoma undergoing potentially curative gastrectomy from 1989 to 2010 were identified from the SEER registry and two single institution databases from the US and Korea. Patients were categorized into three groups: Koreans born/treated in Korea (KK), Koreans born in Korea/treated in the US (KUS), and White Americans born/treated in the US (W), and disease-specific survival rates compared.
RESULTS
We identified 16,622 patients: 3,984 (24.0%) KK, 1,046 (6.3%) KUS, and 11,592 (69.7%) W patients. KK patients had longer unadjusted median (not reached) and 5-year disease-specific survival (81.6%) rates than KUS (87 months, 55.9%) and W (35 months, 39.2%; p < 0.001 for all comparisons) patients. This finding persisted on subset analyses of patients with stage IA tumors, without cardia/GEJ tumors, with > 15 examined lymph nodes, and treated at a US center of excellence. On multivariable analysis, KUS (HR 2.80, p < 0.001) and W (HR 5.79, p < 0.001) patients had an increased risk of mortality compared to KK patients.
CONCLUSIONS
Both the place of birth and the place of treatment significantly contribute to the improved prognosis of patients with gastric cancer in Korea relative to those in the US, implicating both nature and nurture in this phenomenon.
Identifiants
pubmed: 30167904
doi: 10.1007/s10120-018-0869-z
pii: 10.1007/s10120-018-0869-z
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
446-455Références
N Engl J Med. 1999 Mar 25;340(12):908-14
pubmed: 10089184
Br J Cancer. 1999 Mar;79(9-10):1522-30
pubmed: 10188901
Cancer. 2000 Nov 1;89(9):1883-92
pubmed: 11064344
Cancer. 2000 Dec 1;89(11):2237-46
pubmed: 11147594
Eur J Surg Oncol. 2002 Apr;28(3):214-9
pubmed: 11944952
N Engl J Med. 2002 Apr 11;346(15):1128-37
pubmed: 11948273
J Clin Oncol. 2004 Jun 1;22(11):2069-77
pubmed: 15082726
World J Gastroenterol. 2006 Jan 21;12(3):354-62
pubmed: 16489633
Ann Surg. 2007 Mar;245(3):426-34
pubmed: 17435550
Eur J Surg Oncol. 2008 Jan;34(1):36-41
pubmed: 17442532
J Surg Oncol. 2007 Jul 1;96(1):14-8
pubmed: 17582596
Health Aff (Millwood). 2007 Sep-Oct;26(5):1258-68
pubmed: 17848435
N Engl J Med. 2008 Jul 31;359(5):453-62
pubmed: 18669424
Int J Cancer. 2009 Aug 1;125(3):666-73
pubmed: 19382179
Ann Surg Oncol. 2009 Sep;16(9):2433-41
pubmed: 19582508
Ann Oncol. 2010 Jan;21(1):152-60
pubmed: 19622590
Cancer. 2009 Oct 1;115(19):4595-605
pubmed: 19626648
Ann Surg. 2010 Apr;251(4):640-6
pubmed: 20224369
Ann Surg Oncol. 2010 Dec;17(12):3077-9
pubmed: 20882416
World J Gastroenterol. 2011 Jun 7;17(21):2602-10
pubmed: 21677827
J Gastric Cancer. 2011 Sep;11(3):135-40
pubmed: 22076217
J Surg Oncol. 2013 May;107(6):634-40
pubmed: 23192297
Dig Surg. 2013;30(2):96-103
pubmed: 23867585
Br J Surg. 2014 Jan;101(2):23-31
pubmed: 24375296
Ann Surg Oncol. 2014 Jul;21(7):2332-9
pubmed: 24599411
World J Gastroenterol. 2014 Sep 7;20(33):11546-51
pubmed: 25206261
World J Gastroenterol. 2014 Sep 28;20(36):12883-91
pubmed: 25278685
Ann Surg Oncol. 2015 Sep;22(9):2965-71
pubmed: 25631065
Am Surg. 2015 Mar;81(3):259-67
pubmed: 25760201
J Gastrointest Surg. 2015 Nov;19(11):1966-73
pubmed: 26307345
Cancer. 1989 Nov 15;64(10):2053-62
pubmed: 2680049
Gastric Cancer. 2017 Jul;20(4):573-582
pubmed: 27866287
Lancet. 1995 Mar 25;345(8952):745-8
pubmed: 7891484
J Natl Cancer Inst. 1977 Jan;58(1):13-20
pubmed: 833857
Lancet. 1997 Jun 14;349(9067):1725-9
pubmed: 9193382
Ann Surg. 1998 Oct;228(4):449-61
pubmed: 9790335